RxDoctor Payments Data

Lisa Knust, MD

Family Medicine · Carrollton, VANPI 1336179134

Payments from drug & device makers

$5,802in general payments, 2019–2025

Across 169 payments — averaging $34.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$950
  • Johnson & Johnson$747
  • Lilly USA, LLC$715
  • AstraZeneca$531
  • AbbVie$451
  • Biohaven Pharmaceuticals, Inc.$339
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,75299%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,802 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$172,227
Medicare patients
441
Services billed
4,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide75$92,127
OzempicSemaglutide53$83,597
EliquisApixaban74$68,285
JanuviaSitagliptin Phosphate82$66,906
JardianceEmpagliflozin53$48,076
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,363
FarxigaDapagliflozin Propanediol12$18,126
LinzessLinaclotide18$16,780
Tresiba Flextouch U-200Insulin Degludec11$15,707
XareltoRivaroxaban12$14,386
MyrbetriqMirabegron14$12,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$12,067
Trijardy XrEmpaglifloz/Linaglip/Metformin11$9,260
Xigduo XrDapaglifloz Propaned/Metformin16$9,047
Albuterol Sulfate HfaAlbuterol Sulfate161$5,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$715$92,12775 claims
Novo NordiskOzempic$950$83,59753 claims
PfizerEliquis, Premarin, Paxlovid$124$73,634110 claims
MerckJanuvia, Belsomra$68$71,61493 claims
Boehringer IngelheimJardiance, Trijardy Xr$316$57,33664 claims
GSKTrelegy Ellipta, Breo Ellipta$272$28,65947 claims
AbbVieLinzess, Synthroid$451$19,86485 claims
AstraZenecaFarxiga$531$18,12612 claims
Johnson & JohnsonXarelto$747$14,38612 claims
Astellas Pharma US IncMyrbetriq$35$12,39114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Carrollton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →